Coreline Soft "Targeting Remote Diagnosis Market in Japan Following UK"

Coreline Soft announced on the 14th that it is currently in discussions to supply its proprietary artificial intelligence (AI) software (SW) ‘AVIEW LCS Plus’ to ‘Company A,’ a leading Japanese remote diagnosis company. Based on the world’s number one AI technology, Coreline Soft plans to strengthen its global remote diagnosis market presence in Japan following the UK.

The company currently in supply discussions holds a dominant position in the Japanese remote diagnosis market. Company A receives CT (computed tomography) images from medical institutions and interprets whether patients have lung diseases. In the process of identifying AI software to use for interpretation, they explored related products in the global market and recently proactively proposed supply to Coreline Soft, which demonstrated outstanding performance.

Coreline Soft is expanding its application area to remote diagnosis based not only on its outstanding AI technology but also on excellent interoperability. The AI software has been advanced to be compatible not only with medical institution interpretation systems (PACS) but also with the workflows of remote diagnosis companies. Through this, last year, Coreline Soft entered the remote diagnosis market by signing a supply contract for AVIEW LCS Plus with DMC Healthcare, the solution provider for the UK government-led lung cancer screening project.

Coreline Soft recently proved through an international academic journal that its proprietary AI software outperforms the product of the world’s leading medical imaging diagnosis company in all performance indicators. Recognized for its AI technological competitiveness, the company explained that it continues to receive inquiries for AI software adoption from various global remote diagnosis companies beyond the UK and Japan.

Along with continuous AI technology advancement, Coreline Soft is also expanding international certifications. During the commercialization process of the solution, it obtained certifications such as the U.S. Food and Drug Administration (FDA) and European CE certification. Earlier this year, it simultaneously acquired certifications for the ‘U.S. Health Insurance Portability and Accountability Act (HIPAA)’ and the ‘European General Data Protection Regulation (GDPR),’ the world’s most prestigious certifications in the medical AI field, thereby strengthening entry barriers.

A Coreline Soft official stated, “Since signing the AI software supply contract with a UK remote diagnosis specialist company last year, inquiries for Coreline Soft’s AI software adoption have continued from various global companies,” adding, “Because we have already obtained all the necessary approvals and certifications required for remote diagnosis companies, not only with outstanding AI technology but also with essential regulatory compliance, Coreline Soft’s entry into the global remote diagnosis market will accelerate.”

He continued, “AVIEW LCS Plus has already been supplied to Germany, Italy, and five other European countries, building customer trust. Its strengths lie not only in its outstanding AI technology but also in its excellent interoperability,” adding, “We will continue to focus on performance growth centered on remote diagnosis, which contributes significantly to our results, by maximizing our proprietary AI technology and interoperability.”